| Methods |
Single centre, double blind, placebo controlled, single dose, crossover trial ,
Duration 2 single treatment days separated by a 4 week washout phase |
| Participants |
12 adult patients, 11 male 1 female.Mean age 34 years (Range 18‐66 years)Exclusion criteriaUnder 18, history of psychosis and schizophrenia, significant concomitant illness, or pregnant. |
| Interventions |
THC 5.0 or 7.5 or 10.0 mg vs. placebo |
| Outcomes |
1.Tic severity patient rated using Tourette's Syndrome Symptom list TSSL.2. Tic examiner rated using Shapiro Tourette's Syndrome Severity Scale STSS, Yale Global Tic Severity Scale YGTSS, and Tourette Syndrome Global Scale TSGS, 3. Patients also rated severity of impulse control; Obsessive Compulsive Behaviours OCB, subdivided into obsessions and compulsions such as checking ordering doing things "just right", counting, rituals, washing and doing things an exact number of times;anxiety;depression;Attention Deficit Hyperctivity Disorder ADHD; and Premonitory experiences PE, prior to tics before and after treatment;Patient rated global change and Adverse reactions |
| Notes |
|
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Allocation concealment? |
Low risk |
A ‐ Adequate |
